{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:29Z","timestamp":1790351429197,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125037"],"award-info":[{"award-number":["82125037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873057"],"award-info":[{"award-number":["81873057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["H2023077"],"award-info":[{"award-number":["H2023077"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308200"],"award-info":[{"award-number":["2023YFC2308200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bcp.2025.116763","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T11:05:22Z","timestamp":1737198322000},"page":"116763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both imatinib-sensitive and imatinib-resistant CML cells"],"prefix":"10.1016","volume":"233","author":[{"given":"Xiaoyan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pematenzin","family":"Puno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bcp.2025.116763_b0005","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.bcp.2025.116763_b0010","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1172\/JCI31988","article-title":"Applying the discovery of the Philadelphia chromosome","volume":"117","author":"Sherbenou","year":"2007","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.bcp.2025.116763_b0015","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","article-title":"A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.116763_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","article-title":"The thioredoxin antioxidant system","volume":"66","author":"Lu","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.bcp.2025.116763_b0025","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-019-03912-4","article-title":"The thioredoxin system and cancer therapy: a review","volume":"84","author":"Mohammadi","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"16","key":"10.1016\/j.bcp.2025.116763_b0030","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1021\/acs.jmedchem.8b01595","article-title":"Targeting the Thioredoxin System as a Strategy for Cancer Therapy","volume":"62","author":"Bian","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116763_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101400","article-title":"Modification of Cys residues in human thioredoxin-1 by p-benzoquinone causes inhibition of its catalytic activity and activation of the ASK1\/p38-MAPK signalling pathway","volume":"29","author":"Shu","year":"2020","journal-title":"Redox Biol."},{"issue":"23","key":"10.1016\/j.bcp.2025.116763_b0040","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1158\/1078-0432.CCR-05-0449","article-title":"High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer","volume":"11","author":"Kim","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2025.116763_b0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/antiox10010104","article-title":"Investigating the Thioredoxin and Glutathione Systems\u2019 Response in Lymphoma Cells after Treatment with [Au(d2pype)2]Cl","volume":"10","author":"Wang","year":"2021","journal-title":"Antioxidants"},{"issue":"6","key":"10.1016\/j.bcp.2025.116763_b0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41557-019-0261-6","article-title":"Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis","volume":"11","author":"Llabani","year":"2019","journal-title":"Nat. Chem."},{"key":"10.1016\/j.bcp.2025.116763_b0055","doi-asserted-by":"crossref","unstructured":"Y. X. Xiong, Q, F. Zhao, A Hua, X. Wang, X. Chen, X. L. Yang, Z. F. Li Hydroxyethyl starch-based self-reinforced nanomedicine inhibits both glutathione and thioredoxin antioxidant pathways to boost reactive oxygen species-powered immunotherapy, Biomaterials 311 (2024) 122673.","DOI":"10.1016\/j.biomaterials.2024.122673"},{"key":"10.1016\/j.bcp.2025.116763_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121110","article-title":"Application of glutathione depletion in cancer therapy Enhanced ROS-based therapy: ferroptosis, and chemotherapy","volume":"277","author":"Niu","year":"2021","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.bcp.2025.116763_b0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41419-024-06923-z","article-title":"Glutathione overproduction mediates lymphoma initiating cells survival and has a sex-dependent effect on lymphomagenesis","volume":"15","author":"Alc\u00e1ntara","year":"2024","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bcp.2025.116763_b0070","first-page":"2911","article-title":"Glutamate-cysteine ligase catalytic subunit as a therapeutic target in acute myeloid leukemia and solid tumors","volume":"11","author":"Lin","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10.1016\/j.bcp.2025.116763_b0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","article-title":"Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression","volume":"27","author":"Harris","year":"2015","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.bcp.2025.116763_b0080","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.scib.2021.02.010","article-title":"The role of iron homeostasis in remodeling immune function and regulating inflammatory disease","volume":"66","author":"Mu","year":"2021","journal-title":"Science Bulletin"},{"issue":"7860","key":"10.1016\/j.bcp.2025.116763_b0085","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bcp.2025.116763_b0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","article-title":"Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion","volume":"19","author":"Friedmann Angeli","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2025.116763_b0095","first-page":"4327","article-title":"Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer, Nature","volume":"13","author":"Bartolacci","year":"2022","journal-title":"Communications"},{"issue":"2","key":"10.1016\/j.bcp.2025.116763_b0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3324\/haematol.2022.280786","article-title":"Genome-wide CRISPR screens identify ferroptosis as a novel therapeutic vulnerability in acute lymphoblastic leukemia","volume":"108","author":"Lalonde","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2025.116763_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102408","article-title":"Acute lymphoblastic leukemia necessitates GSH-dependent ferroptosis defenses to overcome FSP1-epigenetic silencing","volume":"55","author":"Pontel","year":"2022","journal-title":"Redox Biol."},{"issue":"4","key":"10.1016\/j.bcp.2025.116763_b0110","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/0008-5472.CAN-16-0987","article-title":"The Natural Diterpenoid Isoforretin A Inhibits Thioredoxin-1 and Triggers Potent ROS-Mediated Antitumor Effects","volume":"77","author":"Sun","year":"2017","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.116763_b0115","first-page":"1961","article-title":"d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors","volume":"2","author":"Vanhoefer","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2025.116763_b0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cmet.2020.12.007","article-title":"Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis","volume":"33","author":"Kang","year":"2021","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2025.116763_b0125","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1038\/s41467-023-39901-8","article-title":"ACTL6A protects gastric cancer cells against ferroptosis through induction of glutathione synthesis","volume":"14","author":"Yang","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2025.116763_b0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116763_b0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: a novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2025.116763_b0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"APR-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcp.2025.116763_b0145","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s10020-024-01002-7","article-title":"Hyperoside induces ferroptosis in chronic myeloid leukemia cells by targeting NRF2","volume":"30","author":"Wei","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2025.116763_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101977","article-title":"ent-Kaurane diterpenoids induce apoptosis and ferroptosis through targeting redox resetting to overcome cisplatin resistance","volume":"43","author":"Sun","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2025.116763_b0155","doi-asserted-by":"crossref","unstructured":"Xu, Cong et al. \u03b2-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer. Pharmacological research vol. 191 (2023): 106739.","DOI":"10.1016\/j.phrs.2023.106739"},{"key":"10.1016\/j.bcp.2025.116763_b0160","doi-asserted-by":"crossref","unstructured":"X.S. Xin Chen, Chong Zhao, Xiaofen Li, Xiaoying Lan, Shouting Liu,Hongbiao Huang, Ningning Liu, Siyan Liao, Dan Zang, Wenbin Song, Quentin Liu, Bing Z. Carter, Q. Ping Dou, Xuejun Wang, Jinbao Liu, Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms, Oncotarget 5(19) (2014) 2361.","DOI":"10.18632\/oncotarget.2361"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:05:55Z","timestamp":1777381555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"alternative-id":["S0006295225000255"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116763","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both imatinib-sensitive and imatinib-resistant CML cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116763"}}